放射联合顺铂治疗鼻咽癌的前瞻性临床研究

Prospective Randomized Trial of Radiotherapy plus Cisp latin ( CDDP) for Nasopharyngeal Carcinoma

９８例己确诊为鼻咽癌病例随机分为单纯放射组（４８例）和放射治疗综合应用顺铂组（５０例）。放射治疗全部采用同中心治疗，总剂量７０Ｇｙ／３５－３７次／７—８周。顺铂自放射开始后第二天使用，１次／周，２０ｍｇ／ｍ２／次。在治疗结束后三月评价，放射联合顺铂组和单纯放射组的原发肿瘤完全消退率分别为９２％和６８．７５％，颈部转移灶的完全消退率分别为９０．６％和６９．４％，两组经统计学处理均有显著性差异。随访三年（中位随访期４０月），三年生存率分别为综合治疗组８３％和单纯放射射组７６％。两组急性反应和后期反应无显著差异，所有病人均能耐受而完成治疗计划。

98 patients with nasopharyngeal carcioma were randomized Single radiotherapy group(Arml.48 cases) and radiotherapy plus CDDP Group (Arm2.50 cases).Radiotherapy was isocentry treatment for all patients and the total doses of 70GY/35-37 fractions / 7-8 weeks.The cisplatin was given 20mg/m 2 once a week for 7-8 weeks. The results was that patients in arm2 had higher CR rate than in Arm l.Followed up three years (median 40 months) the three years survival rate was 76% in Arm l and 83% in Arm 2.The acute reaction and the late reaction were more severe in Arm2 than that observed in Arm l, but all were tolerable.